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1Atherosclerotic vascular disease is a chronic disease of the arterial wall of different vascular territories, causing cere-
brovascular, coronary, peripheral, and aortic vascular disease. It 
is the leading cause of death and morbidity worldwide.1 Vascular 
risk factors, such as hypertension and hypercholesterolemia are 
important drivers of atherosclerosis2–5 and blood pressure low-
ering, lipid-lowering, and antiplatelet treatment are effective in 
reducing acute vascular events both in primary and secondary 
prevention settings.6–9 Recent randomized trials showed that 
novel anti-inflammatory and lipid-lowering therapies reduced 
risk of recurrent cardiovascular events in patients with car-
diovascular disease on current standard secondary prevention 
treatment.10–12 However, these new agents are expensive and are 
unlikely to be cost-effective in patients at low vascular risk.
Patients in the secondary prevention setting with athero-
sclerotic disease affecting 2 or more vascular beds seem to 
be at high risk for future vascular events.13,14 However, previ-
ous studies were hospital-based, had a relatively short follow-
up, and did not focus specifically on patients with transient 
ischemic attack (TIA) and stroke. To assess whether TIA/
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Background and Purpose—Cerebrovascular, coronary, and peripheral vascular disease have common underlying arterial 
pathology and risk factors, but the clinical significance of multiple-territory disease in patients with transient ischemic 
attack (TIA)/ischemic stroke is unclear, particularly whether the number of clinically affected territories still predicts 
long-term outcome on current standard secondary prevention therapies.
Methods—In a population-based study of 92 728 individuals in Oxfordshire, United Kingdom (Oxford Vascular Study), 
we studied patients presenting with TIA/ischemic stroke (2002–2014) in relation to the number of other vascular beds 
(coronary, peripheral) affected by symptomatic (current or previous) disease. We compared the risk factor profile and 
long-term prognosis in patients with single- versus multiple-territory disease.
Results—Among 2554 patients with 10 679 patient-years of follow-up, 1842 (72.1%) had single- (TIA/stroke only), 608 
(23.8%) double-, and 104 (4.1%) triple-territory symptomatic vascular disease. The number of affected vascular beds 
increased with the number of atherosclerotic risk factors (Ptrend<0.0001). Compared with patients with TIA/stroke only, 
those with multiple-territory disease had more hypertension (age/sex-adjusted odds ratio [OR], 3.43; 95% confidence 
interval [CI], 2.76–4.27; P<0.0001), diabetes mellitus (OR, 2.89; 95% CI, 2.27–3.66; P<0.0001), hypercholesterolemia 
(OR, 4.67; 95% CI, 3.85–5.66; P<0.0001), and current or previous smoking (OR, 1.52; 95% CI, 1.26–1.84; P<0.0001). 
Triple-territory disease was particularly strongly associated with hypercholesterolemia (OR, 6.80; 95% CI, 4.39–10.53; 
P<0.0001). Despite more intensive secondary prevention in patients with multiple-territory disease, the 5-year risk of 
vascular death increased steeply with the number of territories affected (17.2% versus 30.0% versus 42.9%; P<0.0001). 
Compared with patients with single-territory, patients with multiple-territory disease also had higher postacute long-term 
risks (90 days to 10 years) of recurrent ischemic stroke (age/sex-adjusted hazard ratio, 1.38; 95% CI, 1.04–1.81; P=0.02) 
and nonstroke acute vascular events (hazard ratio, 3.06; 95% CI, 2.23–4.20; P<0.0001).
Conclusions—Number of affected vascular beds appeared to be a simple clinical rule in identifying TIA/ischemic stroke 
patients who are at high long-term risk of nonstroke vascular events and vascular death.   (Stroke. 2018;49:00-00. 
DOI: 10.1161/STROKEAHA.118.020913.)
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2  Stroke  July 2018
ischemic stroke patients with disease in other vascular beds 
were at particularly high risk of future vascular events as pre-
viously suggested,13,14 we studied patients presenting with TIA 
or ischemic stroke in relation to the number of other vascular 
beds (coronary, peripheral) affected by symptomatic disease 
to determine long-term prognosis on current standard second-
ary prevention in a population-based study. We hypothesized 
that the number of affected vascular beds could be used as a 
simple clinical rule in identifying patients who are at high risk 
of recurrent vascular events.
Methods
Requests for access to data from OXVASC will be considered by the 
corresponding author.
We studied consecutive patients with a first-in-the-study-period 
TIA or ischemic stroke in OXVASC (Oxford Vascular Study) from 
2002 to 2014. OXVASC is an ongoing population-based study of the 
incidence and outcome of all acute vascular events in a population 
of 92 728 individuals, registered with 100 general practitioners in 
9 general practices in Oxfordshire, United Kingdom. The multiple 
overlapping methods used to achieve near complete ascertainment 
of all individuals with TIA and ischemic stroke have been reported 
previously.15 Briefly, these included (1) a daily, rapid-access TIA, 
and stroke clinic to which participating general practitioners and the 
local emergency department team referred individuals with suspected 
TIA or minor stroke; (2) daily searches of admissions to medical, 
stroke, neurology, and other relevant wards; (3) daily searches of the 
local emergency department attendance register; (4) daily searches 
of in-hospital death records via the bereavement office; (5) monthly 
searches of all death certificates and coroner’s reports for out-of-hos-
pital deaths; (6) monthly searches of general practitioner diagnostic 
coding and hospital discharge codes; and (7) monthly searches of all 
brain and vascular imaging referrals.
Demographic data, risk factors for atherosclerosis (eg, hyperten-
sion, diabetes mellitus, history of smoking, hypercholesterolemia), 
and history of vascular disease in other vascular beds (symptomatic 
coronary and peripheral vascular disease) were collected from face-
to-face interview and cross-referenced with primary care records.
Patients were considered to have concurrent coronary heart 
disease if they had at least one of the following conditions: previ-
ous myocardial infarction; unstable angina; angina; and history of 
percutaneous coronary intervention or coronary artery bypass graft 
surgery. Concurrent symptomatic peripheral vascular disease was 
defined as having at least one of the following conditions: previ-
ous aortic aneurysm rupture; aortic dissection; acute limb ischemia; 
critical limb ischemia; acute visceral ischemia; intermittent claudi-
cation; previous angioplasty or stenting; peripheral arterial bypass 
graft or amputation. Patients without a history of symptomatic coro-
nary or peripheral vascular disease were classified as having single-
territory disease (TIA/stroke only), whereas patients with concurrent 
coronary or peripheral vascular disease were classified as having 
double-territory disease and patients with diseases in both coronary 
and peripheral vascular beds were classified as having triple-territory 
symptomatic vascular disease.
All patients routinely had brain imaging (computed tomography 
or magnetic resonance imaging), intracranial and extracranial vascu-
lar imaging (carotid Doppler/CTA/MRA/DSA), 12-lead electrocardi-
ography, and routine bloods (ie, full blood count, clotting, C-reactive 
protein, erythrocyte sedimentation rate, liver function, renal func-
tion, thyroid function, electrolytes, and lipid profile) after the event. 
Echocardiography, 24-hour electrocardiography, and 5-day electro-
cardiography event recorder (R test) were also done when clinically 
indicated. Standard secondary preventive treatment was continued 
or started on the day of the initial clinical assessment, which usu-
ally included antithrombotic treatment, antihypertensive drugs, and 
a statin. Notably, although we routinely prescribed a statin, the exact 
regime continued for long-term use (ranging from simvastatin 40 mg 
daily to atorvastatin 80 mg daily) was left to the patient’s primary care 
physician, who has a responsibility in the UK healthcare system for 
long-term management of patients.
Patients were followed-up face-to-face at 1, 6, 12, 60, and 120 
months by a study nurse or physician to identify any recurrent stroke 
and other acute vascular events (myocardial infarction, peripheral 
vascular event), supplemented by review of primary care records. 
Patients who had moved out of the study area were followed-up 
via telephone at the same time points as face-to-face follow-up. We 
recorded all deaths during follow-up with the underlying causes by 
direct follow-up, via primary care records, and by centralized reg-
istration with Office for National Statistics. All recurrent events that 
occurred during follow-up would also be identified by the ongoing 
daily case ascertainment.
Statistical Analysis
Baseline characteristics were compared between all 3 groups (sin-
gle-territory versus double-territory versus triple-territory), using χ2 
test for categorical variables and 1-way ANOVA test for continuous 
variables.
We compared the prevalence of atherosclerotic risk factors 
(overall number and individual risk factors) and also prevalence of 
asymptomatic carotid disease (based on vascular imaging performed 
routinely for all patients as part of the diagnostic workup) in patients 
with single- versus multiple-territory disease using χ2 test and logistic 
regression analysis adjusted for age and sex.
Kaplan-Meier survival analysis was used to calculate the 1-year, 
5-year, and 10-year risks of vascular events during follow-up, cen-
sored at death or September 30, 2014, for single-, double-, and triple-
territory disease. We compared the following outcomes in patients 
with single- versus multiple-territory disease using Cox-regression 
analysis adjusted for age and sex: first major cardiovascular event 
(any recurrent ischemic stroke, myocardial infarction, acute periph-
eral vascular event, or vascular death), vascular death, first recurrent 
ischemic stroke, and first nonstroke acute vascular event (myocardial 
infarction, acute peripheral vascular event, or sudden cardiac death). 
Exploratory analyses were performed with additional adjustment for 
other known vascular risk factors.
Sensitivity analyses were also performed confined to patients 
with large artery disease according to TOAST classification (Trial 
of ORG 10172 in Acute Stroke Treatment), excluding patients with 
known atrial fibrillation at baseline and stratified by the type of the 
index event (TIA versus ischemic stroke).
All analyses were done using SPSS version 22.
Standard Protocol Approvals, Registrations, and  
Patient Consents
Written informed consent or assent from relatives was obtained in 
all participants. OXVASC was approved by the local research ethics 
committee (OREC A: 05/Q1604/70).
Results
Of 2554 patients with a first-in-the-study-period event (1606 
ischemic stroke and 948 TIA), 1842 (72.1%) had single-ter-
ritory disease (TIA/ischemic stroke only), 608 (23.8%) had 
double-territory, and 104 (4.1%) had triple-territory symptom-
atic vascular disease.
As shown in Table 1, patients with double- or triple-ter-
ritory disease were more likely to be on preventative agents 
for vascular disease before the index TIA/stroke. The propor-
tion of patients on secondary prevention further increased 
after the index event for all patients (Table 1) but was more 
intensive in patients with multiple-territory disease (Table 1). 
At 1-month follow-up, 84 (95.5%) of the 88 patients with 
triple-territory disease were on antithrombotic agents, 74 
(84.1%) on antihypertensive treatment, and 73 (83.0%) were 
on statins (Table 1). At 1-year follow-up, 72 (97.3%) of the 74 
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patients with triple-territory disease remained on antithrom-
botic agents, 63 (85.1%) on antihypertensive treatment, and 
61 (82.4%) were still on statins (Table 1).
As shown in Figure 1, the number of affected vascular 
beds increased with the numbers of atherosclerotic risk factors 
(Ptrend<0.0001), with the highest prevalence in patients with 
triple-territory disease (Table 1). Compared with patients with 
TIA/stroke only, those with double- or triple-territory disease 
had more hypertension (age/sex-adjusted odds ratio [OR], 
3.43; 95% confidence interval [CI], 2.76–4.27; P<0.0001; 
Table 2), diabetes mellitus (OR, 2.89; 95% CI, 2.27–3.66; 
P<0.0001; Table 2), hypercholesterolemia (OR, 4.67; 95% 
CI, 3.85–5.66; P<0.0001; Table 2), and history of smoking 
(OR, 1.52; 95% CI, 1.26–1.84; P<0.0001; Table 2). The same 
Table 1. Demographics, Risk Factors, and Secondary Prevention Treatment in Patients With Baseline Single-, 
Double-, and Triple-Territory Diseases
 Single-Territory (n=1842) Double-Territory (n=608) Triple-Territory (n=104) P Value*
Age (mean and SD) 72.4 (13.7) 77.9 (10.1) 78.2 (9.3) <0.0001
Sex    0.0001
  Male 871 (47.3) 322 (53.0) 69 (66.9)  
  Female 971 (52.7) 286 (47.0) 35 (33.7)  
Index event    0.01
  Transient ischemic attack 713 (38.7) 202 (33.2) 34 (32.7)  
  Minor ischemic stroke 
(NIHSS<5)
757 (41.1) 246 (40.5) 44 (42.3)  
  Major ischemic stroke 
(NIHSS≥5)
372 (20.2) 160 (26.3) 26 (25.0)  
Vascular risk factors
  History of hypertension 1014 (55.0) 495 (81.4) 90 (86.5) <0.0001
  History of diabetes mellitus 190 (10.3) 140 (23.0) 27 (26.0) <0.0001
  History of 
hypercholesterolemia
481 (26.1) 351 (57.7) 70 (67.3) <0.0001
  Known atrial fibrillation at 
baseline
443 (24.0) 253 (41.6) 42 (40.4) <0.0001
  History of cardiac failure 93 (5.0) 140 (23.0) 28 (26.9) <0.0001
  History of smoking† 973 (53.0) 361 (59.3) 82 (78.8) <0.0001
  Current smoker‡ 288 (15.7) 56 (9.2) 17 (16.3) 0.0003
Premorbid use of preventative agents
  Antithrombotic agents 556 (30.2) 457 (75.2) 93 (89.4) <0.0001
  Antihypertensive agents 899 (48.8) 501 (82.4) 86 (82.7) <0.0001
  Statin 294 (16.0) 326 (53.6) 64 (61.5) <0.0001
Secondary prevention at follow-up
  1 mo§ n=1717 n=533 n=88  
   Antithrombotic agents 1612 (93.9)‖ 499 (93.6)‖ 84 (95.5)‖ 0.80
   Antihypertensive agents 1233 (71.8) 463 (86.9) 74 (84.1) <0.0001
   Statin 1266 (73.8) 423 (79.3) 73 (83.0) 0.002
  1 y§ n=1518 n=438 n=74  
   Antithrombotic agents 1396 (92.0) 416 (95.0) 72 (97.3) 0.03
   Antihypertensive agents 1124 (74.0) 385 (87.9) 63 (85.1) <0.0001
   Statin 1185 (78.4) 351 (80.1) 61 (82.4) 0.18
Numbers are presented as number (%) unless otherwise specified. NIHSS indicates National Institutes of Health Stroke Scale.
*P values indicated the heterogeneity across all 3 groups.
†Data missing for 8 patients.
‡Data missing for 7 patients.
§Patients who died before the follow-up were not included.
‖Among patients with known atrial fibrillation at baseline, anticoagulation rates at 1 month for single-, double-, and triple-territory disease 
were 41.8%, 34.5%, and 58.1%, respectively.
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was observed when comparing patients with triple-territory 
disease to patients with TIA/stroke alone (Table 2) and tri-
ple-territory disease was particularly strongly associated with 
known hypercholesterolemia (OR, 6.80; 95% CI, 4.39–10.53; 
P<0.0001; Table 2), with a baseline mean/SD total choles-
terol of 4.5/1.2 mmol/L despite 62% being on statin treatment 
before the index TIA/stroke (Table 1).
Not only did the prevalence of vascular risk factors increase 
with the number of affected vascular beds, but patients with 
multiple-territory disease also had more severe asymptomatic 
carotid bifurcation stenosis (Figure 1). Twenty-six (33.3%) 
of 78 patients in the triple-territory group had at least 50% 
asymptomatic stenosis, compared with 69 (4.8%) of 1441 
patients in the TIA/stroke only group (age/sex-adjusted OR, 
7.39; 95% CI, 4.26–12.81; P<0.0001).
During 10 679 patient-years of follow-up, there were 
515 vascular deaths, 417 recurrent ischemic strokes, and 
203 recurrent nonstroke acute vascular events (136 acute 
coronary events and 67 acute peripheral events). Despite 
more intensive secondary prevention in patients with mul-
tiple-territory disease, the 5-year risks of major cardiovas-
cular event, vascular death, recurrent ischemic stroke, or 
Figure 1. Distribution of numbers of ath-
erosclerotic risk factors (A) and severity of 
asymptomatic carotid bifurcation stenosis 
(B) in patients with single-, double-, and 
triple-territory disease at baseline. History 
of smoking data missing for 8 patients 
in A.
Table 2. Crude and Age/Sex-Adjusted ORs of Different Atherosclerotic Risk Factors in Multiple-Territory vs Single-Territory Events
 
Double/Triple- vs Single-Territory Triple- vs Single-Territory
Crude OR (95% CI) P Value
Age/Sex-Adjusted 
OR (95% CI) P Value Crude OR (95% CI) P Value
Age/Sex-Adjusted 
OR (95% CI) P Value
Age (per y) 1.04 (1.03–1.05) <0.0001 1.05 (1.04–1.05) <0.0001 1.04 (1.02–1.06) <0.0001 1.05 (1.03–1.07) <0.0001
Male sex 1.36 (1.14–1.62) 0.001 1.73 (1.44–2.08) <0.0001 2.20 (1.45–3.34) 0.0002 2.85 (1.85–4.39) <0.0001
Hypertension 3.76 (3.04–4.65) <0.0001 3.43 (2.76–4.27) <0.0001 5.25 (2.97–9.29) <0.0001 5.04 (2.83–8.97) <0.0001
Diabetes mellitus 2.66 (2.12–3.35) <0.0001 2.89 (2.27–3.66) <0.0001 3.05 (1.92–4.85) <0.0001 3.28 (2.04–5.28) <0.0001
Hypercholesterolemia 4.09 (3.41–4.91) <0.0001 4.67 (3.85–5.66) <0.0001 5.83 (3.82–8.89) <0.0001 6.80 (4.39–10.53) <0.0001
History of smoking 1.47 (1.23–1.76) <0.0001 1.52 (1.26–1.84) <0.0001 3.31 (2.05–5.34) <0.0001 3.24 (1.96–5.34) <0.0001
CI indicates confidence interval; and OR, odds ratio.
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recurrent nonstroke acute vascular events increased steeply 
with the number of territories affected (Figure 2; Figure I 
in the online-only Data Supplement). Although the risks 
were particularly front-loading (Figure 2), patients with 
multiple-territory disease also had higher post 90-day long-
term risks of recurrent vascular events (double/triple versus 
single 10-year major cardiovascular events: 50.7% versus 
29.0%; age/sex-adjusted hazard ratio [HR], 1.67; 95% CI, 
1.37–2.01; P<0.0001; Table 3). The risks were higher in 
patients with TIA/stroke plus peripheral vascular disease 
than in patients with TIA/stroke plus coronary artery disease 
(10-year major cardiovascular events: 60.8% versus 46.1%; 
age/sex-adjusted HR, 1.58, 95% CI, 1.03–2.43; P=0.04), and 
were highest in those with triple-territory disease (triple ver-
sus single major cardiovascular events: 64.2% versus 29.0%; 
age/sex-adjusted HR, 2.68; 95% CI, 1.86–3.86; P<0.0001; 
Table 3). Moreover, compared with patients with TIA/stroke 
only, patients with triple-territory disease also had a 2-fold 
increase of recurrent ischemic stroke (10-year age/sex-
adjusted HR, 2.32; 95% CI, 1.39–3.88; P=0.001; Table 3), 
and a 5-fold increase of recurrent nonstroke acute vascular 
events (HR, 4.62; 95% CI, 2.68–7.98; P<0.0001), with the 
risks of recurrent nonstroke acute vascular events approach-
ing the risks of recurrent ischemic stroke (Figure 3).
Sensitivity analysis confined to patients with large artery 
disease (Table I in the online-only Data Supplement), exclud-
ing patients with known atrial fibrillation at baseline (Table II 
in the online-only Data Supplement), or stratified by the type of 
the index event (Table III in the online-only Data Supplement) 
also showed consistent results. Exploratory multivariate analy-
ses adjusting for other vascular risk factors also suggested that 
multiple-territory disease was associated with post 90-day long-
term risks of recurrent cardiovascular events independent of 
age, male sex, history of hypertension, diabetes mellitus, hyper-
cholesterolemia, atrial fibrillation, cardiac failure, and history of 
smoking (Tables IV and V in the online-only Data Supplement).
Discussion
In this population-based study, we showed that over a quar-
ter of patients presenting with TIA or ischemic stroke also 
had known symptomatic disease in other vascular beds. As 
expected, the number of affected vascular beds increased with 
Figure 2. Ten-year risks of recurrent vascular events in patients with baseline single, double, and triple-territory diseases. Panels are for 
different outcomes. A, Major cardiovascular event: any recurrent ischemic stroke, myocardial infarction, acute peripheral vascular event, 
or vascular death; B, vascular death; C, recurrent ischaemic stroke; D, recurrent nonstroke acute vascular event: myocardial infarction, 
acute peripheral vascular event, or sudden cardiac death.
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the numbers of atherosclerotic risk factors. Despite inten-
sive secondary prevention, 10-year risks of recurrent vascu-
lar events increased steeply with the number of territories 
affected. Of particular note, the long-term risks of recurrent 
nonstroke acute vascular events approached the risks of recur-
rent ischemic stroke in patients with multiple-territory disease.
Our findings are in line with previous studies showing that 
despite standard secondary prevention, patients with multiple-
territory disease still had a ≈1.5-fold increase of recurrent 
vascular events or vascular death than patients with TIA or 
ischemic stroke alone.13,14,16–18 However, our estimates of the 
absolute risks were much higher than previous studies, even 
after excluding the acute phase post-TIA/ischemic stroke.13,17 
For example, the 90-day to 1-year vascular death in patients 
with multiple-territory disease was 4.7% in OXVASC versus 
2.8% in the REACH registry (Reduction of Atherothrombosis 
for Continued Health),17 and the risk of all major vascular 
events was 8.6 per 100 patient-years versus 5.0 in the SMART 
study (Second Manifestations of Arterial Disease).13 These 
differences probably reflect the larger number of elderly 
patients with multiple comorbidities in OXVASC owing to the 
population-based design and the longer period of follow-up.
That the number of affected territories still predicts a poor 
outcome in a cohort on current standard secondary prevention 
highlights the unmet need for more effective treatment in TIA 
or ischemic stroke patients with symptomatic disease in multiple 
vascular beds. We found that the number of atherosclerotic risk 
factors increased with the number of affected vascular beds, with 
particularly strong associations with hyperlipidemia, reflecting 
the importance of lipids and smoking in coronary and periph-
eral vascular disease.19,20 Both the recent FOURIER (Further 
Cardiovascular Outcomes Research With PCSK9 Inhibition in 
Subjects With Elevated Risk) and the REVEAL (Randomized 
Evaluation of the Effects of Anacetrapib Through Lipid 
Modification) trials showed that in patients with atherosclerotic 
cardiovascular disease there is some additional benefit from low-
ering of cholesterol levels below current targets.11,12 Although our 
patients with multiple-territory disease were usually on premor-
bid statins, they still had total cholesterol of 4.5 mmol/L at base-
line, and although lipid-lowering was intensified thereafter in the 
majority, additional treatments might be justified.21,22 Moreover, 
previous studies have shown that there is a systemic predispo-
sition to atherosclerosis,23–26 and we found that in patients with 
multiple-territory disease, the long-term risks of nonstroke acute 
vascular events approached the risks of recurrent ischemic stroke.
In our exploratory analyses, we found that numbers of 
affected vascular beds were associated with long-term risks of 
recurrent major cardiovascular events independent of known 
vascular risk factors, and multiple-territory disease seemed to 
be a stronger predictor than vascular risk factors measured at 
baseline. This perhaps reflects the fact that crude prevalence 
of reported vascular risk factors is not always an adequate 
measure of risk because of measurement error, premorbid 
preventative treatment, and different individual susceptibility. 
Hence, the number of affected vascular beds is a perhaps more 
informative summative measure of risk.
Table 3. Post 90-Day Cumulative Risks of Vascular Death, Recurrent Ischemic Stroke, or Recurrent Nonstroke Acute 
Vascular Event Stratified by Number of Affected Vascular Beds at Baseline
Risks by Number of Affected Vascular Beds at Baseline Triple vs Single Double/Triple vs Single
Triple-Territory 
Alone, n (Risk%)
Double/Triple-
Territory, n (Risk%)
Single-Territory, 
n (Risk%)
Adjusted HR  
(95% CI)* P Value
Adjusted HR  
(95% CI)* P Value
Major cardiovascular events†
  1 y 14 (18.8) 52 (10.0) 85 (5.6) 2.90 (1.63–5.17) 0.0003 1.53 (1.08–2.17) 0.02
  5 y 30 (49.1) 142 (34.2) 236 (19.5) 2.58 (1.75–3.80) <0.0001 1.56 (1.26–1.92) <0.0001
  10 y 34 (64.2) 171 (50.7) 277 (29.0) 2.68 (1.86–3.86) <0.0001 1.67 (1.37–2.01) <0.0001
Vascular death
  1 y 8 (9.5) 26 (4.7) 46 (2.8) 2.97 (1.38–6.41) 0.005 1.32 (0.81–2.15) 0.26
  5 y 21 (32.2) 78 (17.5) 121 (9.3) 3.17 (1.97–5.10) <0.0001 1.52 (1.14–2.03) 0.004
  10 y 25 (49.2) 100 (29.0) 148 (15.3) 3.53 (2.29–5.45) <0.0001 1.63 (1.26–2.10) 0.0002
Recurrent ischemic stroke
  1 y 7 (9.4) 26 (5.0) 46 (3.1) 2.63 (1.17–5.94) 0.02 1.40 (0.85–2.30) 0.19
  5 y 14 (25.9) 63 (16.1) 134 (11.6) 2.09 (1.19–3.66) 0.01 1.24 (0.91–1.68) 0.17
  10 y 17 (42.8) 79 (27.8) 154 (16.5) 2.32 (1.39–3.88) 0.001 1.38 (1.04–1.81) 0.02
Recurrent nonstroke acute vascular events‡
  1 y 5 (6.4) 24 (4.4) 13 (0.8) 7.35 (2.50–21.60) 0.0003 5.07 (2.54–10.14) <0.0001
  5 y 16 (25.8) 73 (17.0) 55 (4.6) 5.28 (2.97–9.39) <0.0001 3.34 (2.34–4.76) <0.0001
  10 y 17 (28.7) 86 (24.8) 73 (8.8) 4.62 (2.68–7.98) <0.0001 3.06 (2.23–4.20) <0.0001
CI indicates confidence interval; and HR, hazard ratio. Data are presented as number of events (cumulative risk).
*Adjusted for age and sex.
†Major cardiovascular events: any recurrent ischemic stroke, myocardial infarction, acute peripheral vascular event, or vascular death. 
‡Recurrent nonstroke acute vascular events included myocardial infarction, acute peripheral vascular event, or sudden cardiac death.
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Although we consider our conclusions to be valid, our study 
has limitations. First, we did not screen patients for asymp-
tomatic coronary or peripheral vascular disease and will have 
underestimated the real burden of multiple-territory disease. 
However, screening for asymptomatic coronary or peripheral 
vascular disease is not routine in clinical practice. Moreover, 
even in patients with no known coronary heart disease, statins 
have been shown to reduce major coronary-related events in 
patients with TIA or ischemic stroke.6 Second, although the 
majority of the patients were on a statin during long-term fol-
low-up, the exact regime varied (usually ranging from simvas-
tatin 40 mg daily to atorvastatin 80 mg daily). However, this 
heterogeneity does reflect real-world clinical practice. Third, 
we did not routinely recheck lipid levels during follow-up, as 
this is the responsibility of primary care physicians in the UK 
healthcare system, and so we did not have systematic data on 
the quality of cholesterol control. Fourth, although we used 
several overlapping methods (ie, interviews, ongoing daily 
ascertainment, primary diagnostic coding, death certificates, 
and national hospital coding) to achieve near complete follow-
up, a small proportion of patients (<1%) emigrated from the 
United Kingdom and could not always be followed-up. Finally, 
our results based on a predominantly white population in the 
United Kingdom might not be generalizable to other countries.
To conclude, in a population-based cohort of TIA and 
ischemic stroke patients treated with contemporary standard 
secondary prevention, we found that patients with multiple-ter-
ritory disease had a very high risk of recurrent vascular events 
during long-term follow-up, suggesting that number of affected 
vascular beds could potentially be a simple clinical rule in iden-
tifying patients who are at high risk of recurrent vascular events. 
Our updated risk estimates with contemporary secondary pre-
vention therapies could also help to inform the design of future 
randomized trials. Finally, patients with the multiple-territory 
disease might benefit from more intensive prevention with 
novel therapies and should be the focus of future clinical trials.
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SUPPLEMENTAL MATERIAL 
 
 
 
 
  
Figure I 10-year risks of myocardial infarction/sudden cardiac death and acute peripheral 
vascular events in patients with baseline single, double and triple-territory diseases  
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Triple-territory Double-territory Single-territory 
log rank p<0.0001 log rank p<0.0001 
Table I Post 90-day 5-year risks of death and recurrent vascular events in patients with index TIA or 
ischaemic stroke stratified by number of affected vascular beds at baseline in those with large artery 
disease only 
 
 
Number of affected vascular beds at baseline: Triple vs. single 
 
Double/triple vs. single 
  Triple-territory  Double/triple-territory Single-territory Adjusted HR† p Adjusted HR† p 
  n (risk%) n (risk%) n (risk%) (95%CI)   (95%CI)   
Major cardiovascular events‡ 8 (42.4) 12 (30.1) 23 (17.5) 2.63 (1.16-5.98) 0.02 1.67 (0.91-3.06) 0.10 
Vascular death 3 (16.0) 7 (10.2) 5 (3.4) 3.55 (0.82-15.41) 0.09 2.32 (0.73-7.41) 0.16 
Ischaemic stroke 4 (20.7) 9 (15.1) 13 (10.7) 2.24 (0.72-6.95) 0.16 1.24 (0.53-2.93) 0.62 
Non-stroke events 5 (25.8) 15 (24.0) 11 (8.0) 3.24 (1.07-9.78) 0.04 2.61 (1.18-5.77) 0.02 
Data are presented as number of events (cumulative risk). † adjusted for age and sex. ‡Major cardiovascular events: any 
recurrent ischaemic stroke, myocardial infarction, acute peripheral vascular event or vascular death. 
  
Table II Risks of death and recurrent vascular events in patients with index TIA or ischaemic stroke 
stratified by number of affected vascular beds at baseline, excluding patients with known atrial 
fibrillation at baseline 
 
Number of affected vascular beds at baseline: Triple vs. single 
 
Double/triple vs. single 
  Triple-territory  Double/triple-territory Single-territory Adjusted HR† p Adjusted HR† p 
  n (risk%) n (risk%) n (risk%) (95%CI)   (95%CI)   
Post 90-day to 5-year         
Major cardiovascular events‡ 20 (46.5) 82 (31.6) 169 (17.5) 2.75 (1.72-4.41) <0.0001 1.61 (1.23-2.10) 0.001 
Vascular death 11 (24.9) 35 (12.7) 73 (7.2) 2.84 (1.49-5.41) 0.002 1.37 (0.92-2.06) 0.13 
Ischaemic stroke 11 (27.2) 40 (16.0) 97 (10.3) 2.62 (1.39-4.94) 0.003 1.39 (0.96-2.03) 0.08 
Non-stroke events 12 (26.3) 49 (17.3) 47 (4.9) 4.84 (2.53-9.26) <0.0001 3.17 (2.11-4.75) <0.0001 
Post 90-day to 10-year         
Major cardiovascular events‡ 23 (62.2) 99 (46.0) 202 (26.9) 2.87 (1.85-4.45) <0.0001 1.67 (1.31-2.13) <0.0001 
Vascular death 15 (47.5) 50 (24.5) 91 (12.2) 3.73 (2.14-6.51) <0.0001 1.62 (1.15-2.29) 0.006 
Ischaemic stroke 13 (42.4) 48 (24.3) 113 (14.9) 2.79 (1.56-5.02) 0.001 1.44 (1.02-2.04) 0.036 
Non-stroke events 13 (30.0) 59 (25.9) 64 (9.5) 4.25 (2.31-7.83) <0.0001 2.87 (2.00-4.10) <0.0001 
Data are presented as number of events (cumulative risk). † adjusted for age and sex. ‡Major cardiovascular events: any 
recurrent ischaemic stroke, myocardial infarction, acute peripheral vascular event or vascular death. 
  
Table III Post 90-day 5-year risks of death and recurrent vascular events in patients with index TIA or 
ischaemic stroke stratified by number of affected vascular beds at baseline 
 
Number of affected vascular beds at baseline: Triple vs. single 
 
Double/triple vs. single 
  
Triple- 
territory  
Double/triple- 
territory 
Single- 
territory 
Adjusted HR† p Adjusted HR† p 
  n (risk%) n (risk%) n (risk%) (95%CI)   (95%CI)   
Ischaemic stroke 
      
Major cardiovascular events‡ 18 (44.9) 95 (36.9) 179 (25.5) 1.91 (1.16-3.14) 0.01 1.37 (1.06-1.76) 0.02 
Vascular death 10 (24.1) 45 (16.3) 91 (11.7) 2.14 (1.08-4.22) 0.03 1.20 (0.84-1.72) 0.31 
Ischaemic stroke 9 (25.7) 47 (19.6) 104 (15.8) 1.66 (0.83-3.32) 0.16 1.18 (0.83-1.68) 0.35 
Non-stroke events 9 (22.2) 44 (16.5) 35 (5.1) 4.45 (2.07-9.59) 0.0001 3.12 (1.99-4.89) <0.0001 
TIA 
 
     
Major cardiovascular events‡ 12 (58.9) 47 (29.8) 57 (11.4) 4.86 (2.59-9.12) <0.0001 2.07 (1.40-3.06) 0.0003 
Vascular death 11 (44.7) 33 (19.1) 30 (5.9) 6.92 (3.45-13.89) <0.0001 2.52 (1.53-4.15) 0.0003 
Ischaemic stroke 5 (28.3) 16 (10.4) 30 (6.2) 3.73 (1.44-9.66) 0.007 1.31 (0.71-2.42) 0.39 
Non-stroke events 7 (32.3) 29 (17.8) 20 (4.0) 7.06 (2.93-17.04) <0.0001 3.72 (2.08-6.66) <0.0001 
Data are presented as number of events (cumulative risk). † adjusted for age and sex. ‡Major cardiovascular events: any 
recurrent ischaemic stroke, myocardial infarction, acute peripheral vascular event or vascular death. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table IV Exploratory analyses of the associations of multi-territory disease and post 90-day to 5-year 
risks of recurrent major cardiovascular events adjusting for vascular risk factors 
 
 
  HR (95%CI) p 
Tripe- vs. single-territory 2.01 (1.33-3.04) 0.001 
Age 1.06 (1.04-1.07) <0.0001 
Male sex 0.93 (0.72-1.22) 0.61 
Hypertension 1.25 (0.95-1.65) 0.11 
Diabetes 1.30 (0.92-1.84) 0.13 
Hypercholesterolaemia 1.15 (0.88-1.52) 0.31 
Atrial fibrillation 1.38 (1.05-1.81) 0.02 
Heart failure 1.17 (0.74-1.83) 0.50 
History of smoking 1.30 (1.00-1.69) 0.049 
  HR (95%CI) p 
Tripe/double- vs. single-territory 1.31 (1.04-1.66) 0.02 
Age 1.05 (1.04-1.07) <0.0001 
Male sex 1.00 (0.81-1.25) 0.97 
Hypertension 1.28 (1.00-1.63) 0.049 
Diabetes 1.28 (0.96-1.69) 0.09 
Hypercholesterolaemia 1.08 (0.86-1.35) 0.52 
Atrial fibrillation 1.36 (1.09-1.71) 0.006 
Heart failure 1.04 (0.75-1.45) 0.80 
History of smoking 1.26 (1.01-1.56) 0.04 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table V Exploratory analyses of the associations of multi-territory disease and post 90-day to 5-year 
risks of recurrent ischaemic stroke and recurrent non-stroke acute vascular events adjusting for vascular 
risk factors 
 
A. Recurrent ischaemic stroke 
  HR (95%CI) p 
Tripe- vs. single-territory 1.75 (0.97-3.15) 0.06 
Age 1.04 (1.02-1.05) <0.0001 
Male sex 1.00 (0.71-1.42) 1.00 
Hypertension 1.37 (0.95-1.99) 0.09 
Diabetes 1.31 (0.83-2.08) 0.25 
Hypercholesterolaemia 1.23 (0.86-1.76) 0.27 
Atrial fibrillation 1.45 (1.00-2.11) 0.05 
Heart failure 0.64 (0.29-1.41) 0.27 
History of smoking 0.99 (0.70-1.39) 0.93 
  HR (95%CI) p 
Tripe/double- vs. single-territory 1.08 (0.77-1.50) 0.65 
Age 1.04 (1.02-1.05) <0.0001 
Male sex 1.02 (0.75-1.37) 0.92 
Hypertension 1.26 (0.90-1.75) 0.17 
Diabetes 1.25 (0.84-1.84) 0.27 
Hypercholesterolaemia 1.25 (0.91-1.70) 0.16 
Atrial fibrillation 1.38 (1.01-1.90) 0.04 
Heart failure 0.58 (0.32-1.04) 0.07 
History of smoking 1.02 (0.76-1.37) 0.92 
 
 
 
B. Recurrent non-stroke acute vascular events 
  HR (95%CI) p 
Tripe- vs. single-territory 3.60 (1.91-6.77) <0.0001 
Age 1.07 (1.04-1.09) <0.0001 
Male sex 1.14 (0.68-1.92) 0.63 
Hypertension 1.80 (0.98-3.30) 0.06 
Diabetes 1.63 (0.90-2.97) 0.11 
Hypercholesterolaemia 1.23 (0.73-2.09) 0.43 
Atrial fibrillation 0.60 (0.32-1.14) 0.12 
Heart failure 1.26 (0.55-2.90) 0.58 
History of smoking 1.80 (1.04-3.12) 0.04 
  HR (95%CI) p 
Tripe/double- vs. single-territory 2.80 (1.88-4.16) <0.0001 
Age 1.06 (1.04-1.08) <0.0001 
Male sex 1.31 (0.89-1.91) 0.17 
Hypertension 1.65 (1.02-2.66) 0.04 
Diabetes 1.74 (1.14-2.66) 0.01 
Hypercholesterolaemia 1.03 (0.70-1.53) 0.87 
Atrial fibrillation 0.77 (0.51-1.17) 0.22 
Heart failure 1.03 (0.61-1.75) 0.91 
History of smoking 1.54 (1.04-2.29) 0.03 
 
